Pesquisar
Incyte Corp
INCYAdicionar à lista de desejos
97.844USD
-1.286-1.30%
Horário de mercado （ET）Cotações atrasadas em 15 min
19.42BValor de mercado
13.41P/L TTM
Mais detalhes de Incyte Corp Empresa
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Informações de Incyte Corp
Código da empresaINCY
Nome da EmpresaIncyte Corp
Data de listagemDec 06, 1993
CEOMeury (Bill)
Número de funcionários2617
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 06
Endereço1801 Augustine Cut-Off
CidadeWILMINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19803
Telefone13024986700
Sitehttps://www.incyte.com/
Código da empresaINCY
Data de listagemDec 06, 1993
CEOMeury (Bill)
Executivos da empresa Incyte Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
141.89K
-4.08%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
138.99K
-4.16%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
112.45K
+68.45%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
75.30K
+12.24%
Mr. Thomas R. Tray
Mr. Thomas R. Tray
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
70.94K
+71.74%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
59.31K
+15.54%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
47.17K
+19.54%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
38.04K
-0.29%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
141.89K
-4.08%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
138.99K
-4.16%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
112.45K
+68.45%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
75.30K
+12.24%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
JAKAFI revenues
3.09B
60.15%
OPZELURA revenues
678.46M
13.20%
JAKAVI product royalty revenues
457.73M
8.90%
NIKTIMVO revenues
151.64M
2.95%
Milestone and contract revenues
150.00M
2.92%
Outro
610.91M
11.88%
Por RegiãoUSD
Nome
Receita
Proporção
United States
4.80B
93.36%
Europe
323.73M
6.30%
Other countries
17.57M
0.34%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
JAKAFI revenues
3.09B
60.15%
OPZELURA revenues
678.46M
13.20%
JAKAVI product royalty revenues
457.73M
8.90%
NIKTIMVO revenues
151.64M
2.95%
Milestone and contract revenues
150.00M
2.92%
Outro
610.91M
11.88%
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
15.45%
Dodge & Cox
6.64%
BlackRock Institutional Trust Company, N.A.
5.99%
Vanguard Capital Management, LLC
5.47%
State Street Investment Management (US)
4.83%
Outro
61.62%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
15.45%
Dodge & Cox
6.64%
BlackRock Institutional Trust Company, N.A.
5.99%
Vanguard Capital Management, LLC
5.47%
State Street Investment Management (US)
4.83%
Outro
61.62%
Tipos de investidores
Investidores
Proporção
Investment Advisor
38.80%
Investment Advisor/Hedge Fund
38.57%
Hedge Fund
18.89%
Pension Fund
4.47%
Research Firm
2.12%
Individual Investor
1.92%
Bank and Trust
1.13%
Sovereign Wealth Fund
0.71%
Family Office
0.36%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1617
209.33M
104.84%
-3.76M
2025Q4
1548
207.27M
105.58%
-1.73M
2025Q3
1425
204.09M
103.95%
+86.81K
2025Q2
1423
201.60M
103.23%
-197.50K
2025Q1
1457
199.01M
102.81%
-12.15M
2024Q4
1448
191.80M
99.11%
-19.23M
2024Q3
1401
192.85M
100.02%
-35.92M
2024Q2
1385
209.06M
108.78%
-39.98M
2024Q1
1357
227.85M
101.54%
-21.15M
2023Q4
1323
228.89M
102.19%
-14.49M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
30.74M
15.45%
--
--
Feb 06, 2026
Dodge & Cox
13.26M
6.66%
-670.67K
-4.81%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
11.96M
6.01%
+434.14K
+3.77%
Dec 31, 2025
State Street Investment Management (US)
9.66M
4.85%
-20.39K
-0.21%
Dec 31, 2025
AQR Capital Management, LLC
6.72M
3.38%
-1.20M
-15.19%
Dec 31, 2025
Geode Capital Management, L.L.C.
4.99M
2.51%
+506.84K
+11.30%
Dec 31, 2025
Renaissance Technologies LLC
3.98M
2%
-549.80K
-12.14%
Dec 31, 2025
LSV Asset Management
3.93M
1.98%
-52.34K
-1.31%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Biotechnology & Genome ETF
5.42%
iShares Genomics Immunology and Healthcare ETF
5.11%
First Trust NYSE Arca Biotechnology Index Fund
3.75%
Bushido Capital US Equity ETF
2.47%
AAM Sawgrass US Large Cap Quality Growth ETF
2.44%
First Trust Health Care Alphadex Fund
2.4%
VanEck Biotech ETF
2.34%
Alger Russell Innovation ETF
2.18%
Virtus LifeSci Biotech Products ETF
2.16%
State Street SPDR S&P Biotech ETF
2.13%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção5.42%
iShares Genomics Immunology and Healthcare ETF
Proporção5.11%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.75%
Bushido Capital US Equity ETF
Proporção2.47%
AAM Sawgrass US Large Cap Quality Growth ETF
Proporção2.44%
First Trust Health Care Alphadex Fund
Proporção2.4%
VanEck Biotech ETF
Proporção2.34%
Alger Russell Innovation ETF
Proporção2.18%
Virtus LifeSci Biotech Products ETF
Proporção2.16%
State Street SPDR S&P Biotech ETF
Proporção2.13%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
